Protai Showcases Innovations in Drug Discovery and Proteomics
Protai, a leader in structural proteomics and AI-driven biotechnology, recently took center stage at four key scientific conferences. These events highlight their groundbreaking advances in targeted protein degradation and the use of AI in drug discovery.
Significant Advances Presented at Leading Symposia
At the 13th Symposium on Structural Proteomics, Protai's Head of Proteomics, Dr. Anjana Shenoy, delivered compelling findings on the modeling of TNF? transient pockets. This research integrates AI-driven conformational modeling with mass-spectrometry-based structural proteomics, paving the way for new therapeutics that can effectively modulate TNF signaling. This pathway is crucial in the treatment of various inflammatory and autoimmune diseases.
AI and Structural Proteomics Collaboration
During the MoML@MIT 2025 event, CEO Eran Seger shared insights on how Protai's AIMS™ platform connects AI with structural proteomics. This cutting-edge platform allows for the discovery of dynamic, druggable pockets in complex proteins, including TNF?, enhancing the rational design of small-molecule therapeutics. This strategic innovation addresses limitations faced by traditional structure-based drug discovery methodologies.
Targeted Protein Degradation Innovations
Protai’s CTO, Kirill Pevzner, is set to present accomplishments in targeted protein degradation at the TPD & Induced Proximity Summit. Notably, the development of an innovative KAT6A degrader through the AIMS™ platform demonstrates Protai's commitment to advancing therapeutic options by targeting specific proteins for degradation.
Expanding into Immunology and Inflammation
In addition to these events, Protai will participate in ACR Convergence 2025, a key gathering aimed at expanding their strategic initiatives in the Immunology & Inflammation sector. This involvement underscores the company's growth trajectory and its commitment to addressing crucial medical challenges.
Visionary Leadership and Commitment
Eran Seger emphasizes the company's mission to reshape the discovery of PPI inhibitors and induced proximity therapeutics. He states that combining experimental proteomics with advanced AI modeling reveals potential medical advancements that remain unseen within the confines of classical drug discovery techniques.
About Protai and the AIMS™ Platform
Protai stands at the forefront of structural proteomics and AI-driven biotechnology, using their AIMS™ platform to revolutionize drug discovery processes. By merging mass-spectrometry-driven structural analysis with AI modeling and experimental validation, Protai maps dynamic protein conformations to uncover novel pharmaceutical solutions. Their focus covers vital areas such as oncology and immunology, addressing large-scale clinical needs significantly.
The AIMS™ (AI-Mass-Spectrometry) platform utilizes cutting-edge AI structural modeling alongside experimental proteomics to decode large protein complexes. This innovative approach to drug discovery facilitates the identification of new small molecules and degraders effective for modulating complex biological systems.
Frequently Asked Questions
What is Protai known for?
Protai specializes in structural proteomics and AI-driven drug discovery, focusing on targeted protein degradation.
What are the advantages of the AIMS™ platform?
The AIMS™ platform integrates AI and mass-spectrometry-based proteomics, allowing for the discovery of dynamic druggable pockets in proteins.
Who presented at the 13th Symposium on Structural Proteomics?
Dr. Anjana Shenoy, the Head of Proteomics at Protai, presented breakthrough findings on TNF? transient pocket modeling.
What is the significance of Protai's work in drug discovery?
Protai's work opens new therapeutic avenues for diseases traditionally hard to target with existing drugs.
How is Protai contributing to immunology?
Protai's participation in ACR Convergence 2025 reflects its strategic commitment to advancing therapies in the Immunology & Inflammation area.
